


## CLAIMS

1. A compound of formula



(I)

wherein

m is 0, 1, 2, 3 or 4;

each R<sup>1</sup> independently represents halogen, cyano, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylsulphonyl or sulphonamido (-SO<sub>2</sub>NH<sub>2</sub>);

X represents a bond or -CH<sub>2</sub>- and Y represents a bond or -CH<sub>2</sub>-, provided that X and Y do not both simultaneously represent a bond or -CH<sub>2</sub>-;

n is 0, 1 or 2;

each R<sup>2</sup> independently represents halogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl ;

q is 0 or 1;

p is 0, 1 or 2;

R<sup>3</sup> represents a group selected from halogen, NR<sup>6</sup>R<sup>7</sup>, carboxyl or C<sub>1</sub>-C<sub>6</sub> alkyl wherein said C<sub>1</sub>-C<sub>6</sub> alkyl group is optionally substituted by one or more halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, N-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, N,N-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl;

R<sup>4</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl or halogen;

t is 0, 1 or 2, provided that p and t are not both 0;

R<sup>5</sup> represents a saturated or unsaturated 5- to 10-membered ring system which ring system may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl, -C(O)H, -NR<sup>8</sup>R<sup>9</sup>,

-C(O)NR<sup>10</sup>R<sup>11</sup>, -NHC(O)R<sup>12</sup>, -NHSO<sub>2</sub>R<sup>13</sup>, -SO<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>, -NHC(O)NR<sup>16</sup>R<sup>17</sup>, a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>1</sub>-C<sub>6</sub> alkylsulphonyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, phenylcarbonyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, , phenyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, carboxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy and C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl;

10 R<sup>6</sup> and R<sup>7</sup> each independently represent hydrogen or a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, each of which may be optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy, carbamoyl or C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen atom to which they are attached form a 4- to 7-membered  
15 saturated heterocyclic ring which may be optionally substituted by one or more substituent selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy, carbamoyl or C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl ;

R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> each independently represent hydrogen or a group selected from C<sub>1</sub>-C<sub>6</sub>  
20 alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl; or R<sup>10</sup> and R<sup>11</sup> , together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one  
25 substituent selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl;

R<sup>12</sup> represents hydrogen or a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, each group being optionally substituted by one or more substituents independently selected from  
30 halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl;

R<sup>13</sup> represents a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl;

R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> each independently represent hydrogen or a group selected from C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, each group being optionally substituted by one or more substituents independently selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl; or R<sup>14</sup> and R<sup>15</sup>, or R<sup>16</sup> and R<sup>17</sup>, together with the nitrogen atom to which they are attached each independently form a 4- to 7-membered saturated heterocyclic ring which may be optionally substituted with at least one substituent selected from halogen, amino, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, *N*-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, *N,N*-di-(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, carboxy or carbamoyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein X represents a bond and Y represents -CH<sub>2</sub>-.

3. A compound according to claim 1 or claim 2 wherein q is 1.

4. A compound according to any one of claims 1 to 3 wherein m is 0 or 1 and R<sup>1</sup> represents halogen.

5. A compound according to any one of claims 1 to 4 wherein n is 0.

6. A compound according to any one of claims 1 to 5 wherein R<sup>3</sup> represents halogen, -NR<sup>6</sup>R<sup>7</sup> or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by one or two substituents selected from halogen, amino or hydroxyl

7. A compound according to any one of claims 1 to 6 wherein R<sup>4</sup> represents hydrogen.

8. A compound according to any one of claims 1 to 7 wherein  $R^5$  represents a saturated or unsaturated 5- to 10-membered ring system which ring system may comprise one, two, three or four ring heteroatoms independently selected from nitrogen, oxygen and sulphur and which may be optionally substituted one two or three substituents independently selected from halogen, cyano, oxo, nitro, hydroxyl, carboxyl,  $-C(O)H$ ,  $-NR^8R^9$ ,  $-C(O)NR^{10}R^{11}$ ,  $-NHC(O)R^{12}$ ,  $-NH\text{SO}_2R^{13}$ ,  $-\text{SO}_2NR^{14}R^{15}$ ,  $-NHC(O)NR^{16}R^{17}$ , a group selected from  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylthio,  $C_1$ - $C_6$  alkylsulphonyl,  $C_1$ - $C_6$  haloalkyl,  $C_1$ - $C_6$  alkylcarbonyl, phenylcarbonyl,  $C_3$ - $C_6$  cycloalkyl, , phenyl and a saturated or unsaturated 5- to 6-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, carboxyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  cycloalkyl,  $C_1$ - $C_6$  alkoxy and  $C_1$ - $C_6$  alkoxycarbonyl.

9. A claim according to any one of claims 1 to 8 wherein  $R^5$  represents phenyl, wherein said phenyl is optionally substituted with one or two substituents independently selected from  $-NHC(O)R^{12}$ ,  $-NHC(O)NR^{16}R^{17}$ , hydroxyl or  $C_1$ - $C_6$  alkoxy, or wherein said phenyl is optionally substituted with one, two or three substituents independently selected from halogen, hydroxyl, or carboxyl.

20

10. A compound according to claim 1 selected from:

*N*-(2-{[(2*S*)-2-amino-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-methoxyphenyl)acetamide;

*N*-(2-{[(2*S*)-2-amino-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt);

*N*-(2-{[(2*S*)-2-amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-methoxyphenyl)acetamide;

*N*-(2-{[(2*S*)-2-amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt) ;

*N*-(2-{[(2*S*)-2-Amino-3-(1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-methoxyphenyl)acetamide;

*N*-(2-{[(2*S*)-2-Amino-3-(1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-hydroxyphenyl)acetamide bis(trifluoroacetate) (salt);

*N*-(2-{[(2*S*)-2-(Acetylamino)-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-4-methoxyphenyl)acetamide ;

5 *N*-{2-[3-Amino-2-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl} acetamide bis(trifluoroacetate);

*N*-{2-[3-Amino-2-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl} acetamide bis(trifluoroacetate);

10 *N*-{2-[3-Amino-2-(1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl} acetamide bis(trifluoroacetate);

*N*-{2-[3-Amino-2-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]phenyl} urea bis(trifluoroacetate);

*N*-{2-[3-Amino-2-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]phenyl} urea bis(trifluoroacetate);

15 *N*-{2-[2-Chloro-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-hydroxyphenyl} acetamide trifluoroacetate (salt);

*N*-{2-[2-(5-Chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl} acetamide trifluoroacetate;

20 5-{[(2*S*)-2-Amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}-2*H*-1,4-benzoxazin-3(4*H*)-one;

8-{[(2*S*)-2-Amino-3-(5-fluoro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy} quinolin-2(1*H*)-one;

5-Chloro-2-[2-chloro-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-hydroxybenzoic acid;

25 2-[2-Amino-3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-5-chloro-4-hydroxybenzoic acid;


5-chloro-2-[3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-(methylamino)propoxy]-4-hydroxybenzoic acid;

30 5-chloro-2-[3-(5-chloro-1'*H*,3*H*-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-(dimethylamino)propoxy]-4-hydroxybenzoic acid

and pharmaceutically acceptable salts and solvates of any one thereof.


11. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof which comprises:

(a) converting a compound of formula (II)




wherein  $R^1$ ,  $m$ ,  $X$ ,  $Y$ ,  $R^2$ ,  $n$ ,  $q$ ,  $p$ ,  $R^4$ ,  $t$  and  $R^5$  are as defined in formula (I), into a compound of formula (I); or

10 (b) reacting a compound of formula (III)




15 wherein  $R^1$ ,  $m$ ,  $X$ ,  $y$ ,  $R^2$ ,  $n$  and  $q$  are as defined for formula (I), with a compound of formula (IV)



wherein  $L$  is a leaving group and  $p$ ,  $R^3$ ,  $R^4$ ,  $t$  and  $R^5$  are as defined for formula (I);

20 (c) reacting a compound of formula (V)





wherein  $R^1$ ,  $m$ ,  $X$ ,  $Y$ ,  $R^2$ ,  $n$ ,  $q$ ,  $p$ ,  $R^3$ ,  $R^4$  and  $t$  are as defined for formula (I), with a compound of formula (VI)



5 wherein  $L$  is a leaving group and  $R^5$  is as defined for formula (I);

and optionally thereafter if necessary:

- (i) converting a compound of formula (I) into another compound of formula (I);
- (ii) removing any protecting groups; or
- 10 (iii) forming a pharmaceutically acceptable salt or solvate.

12. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

15

13. A process for the preparation of a pharmaceutical composition as claimed in claim 12 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 with a pharmaceutically acceptable adjuvant, diluent or carrier.

20

14. A compound of formula (I) or a pharmaceutically-acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 for use in therapy.

15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

25

16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in the manufacture of a medicament for use in treating rheumatoid arthritis.

5

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.

10

18. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in the manufacture of a medicament for use in treating asthma.

15

19. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10 in the manufacture of a medicament for use in treating multiple sclerosis.

20

20. A method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10.

25

21. A method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 10.